Uniqure turns the screw on Spark and Pfizer

After a disastrous day for gene therapy yesterday, Uniqure is flying the flag for the sector with its haemophilia B gene therapy candidate AMT-061. The group’s stock got a 7% boost today on further positive data from a three-subject phase IIb trial of the project.